

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

UPDATED INFORMATION ON THE GROUP'S PRODUCT LIRAGLUTIDE INJECTION

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors ("the Board") of the Company is pleased to announce that on 22 August 2023, the application for marketing of Liraglutide Injection for the diabetes indication submitted by Zhuhai United Bio-Pharmaceutical Co., Ltd, a wholly-owned subsidiary of the Company, has been accepted by China National Medical Products Administration, with reference number of CXSS2300067.

Liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, is used for the treatment of adult type 2 diabetes. It can meet the hypoglycemic needs of patients at the dosage of one injection per day. The GLP-1 analog can effectively control blood glucose and reduce the risk of hypoglycemia, while offering weight loss and cardiovascular benefits.

The Company has deployed a differentiated product pipeline covering innovative drugs and biosimilars focusing on GLP-1 target: the application for clinical trial registration of UBT251 injection, a class-I innovative drug, has been accepted on 15 June 2023, helping the Company become the first enterprise in China and the second enterprise in the world to apply for the clinical trial of long-acting triple agonist of GLP-1/GIP/GCG prepared by chemical synthetic polypeptide; semaglutide injection was approved for clinical trials in the diabetes indication on 25 October 2022, and approved for clinical trials in the weight management indication on 17 April 2023.

In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 23 August 2023

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.